Santen completes share buyback, announces cancellation of treasury shares

Santen Pharmaceutical Co., Ltd. announced on November 6, 2025, the completion of its share buyback program. The company repurchased 153,400 common shares for JPY 232,930,350 between November 1 and November 5, 2025. This buyback was executed via an open-market discretionary trading method, aligning with a May 13, 2025, board resolution that authorized the acquisition of up to 19,800,000 common shares for a maximum of JPY 35.0 bn, spanning from May 22, 2025, to November 5, 2025.

In a related development, the company also announced a resolution to cancel 19,800,000 common treasury shares, representing 5.8% of outstanding shares before cancellation, with a scheduled cancellation date of November 28, 2025. This action is based on shares acquired under the May 13, 2025, board resolution, bringing the total repurchased under that resolution to 19,800,000 shares for JPY 31,896,010,850 as of November 5, 2025. The cancellation is projected to result in 322,268,554 outstanding shares and 574,377 treasury shares post-cancellation.